- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.50 Å
- Oligo State
- monomer
- Ligands
- 1 x 1S1: 2-ethyl-2-{[4-(methylamino)-6-(1H-1,2,4-triazol-1-yl)-1,3,5-triazin-2-yl]amino}butanenitrile(Non-covalent)
- 1 x MG: MAGNESIUM ION(Non-covalent)
- 1 x ZN: ZINC ION(Non-covalent)
- 19 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.4: 7 residues within 4Å:- Chain A: T.61, F.62, N.178, L.179, T.180, Q.183
- Ligands: EDO.21
Ligand excluded by PLIPEDO.5: 9 residues within 4Å:- Chain A: R.63, I.64, S.65, T.68, D.174, I.175, M.177, N.178
- Ligands: EDO.14
Ligand excluded by PLIPEDO.6: 9 residues within 4Å:- Chain A: N.136, I.140, D.152, E.153, S.154, V.155, D.199, S.201
- Ligands: EDO.22
Ligand excluded by PLIPEDO.7: 7 residues within 4Å:- Chain A: G.30, L.31, I.33, D.94, K.251, L.255, W.259
Ligand excluded by PLIPEDO.8: 5 residues within 4Å:- Chain A: S.104, T.105, P.106, D.109
- Ligands: EDO.19
Ligand excluded by PLIPEDO.9: 6 residues within 4Å:- Chain A: L.102, T.105, W.311, V.315, D.318, I.322
Ligand excluded by PLIPEDO.10: 5 residues within 4Å:- Chain A: D.193, L.196, A.197, K.202, R.238
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: L.146, M.149, Y.150, H.159, A.162
Ligand excluded by PLIPEDO.12: 9 residues within 4Å:- Chain A: H.87, H.131, G.133, V.134, S.135, E.266, F.267, Q.270
- Ligands: EDO.18
Ligand excluded by PLIPEDO.13: 3 residues within 4Å:- Chain A: S.65, D.67
- Ligands: EDO.14
Ligand excluded by PLIPEDO.14: 6 residues within 4Å:- Chain A: S.65, D.67, T.68, H.172
- Ligands: EDO.5, EDO.13
Ligand excluded by PLIPEDO.15: 4 residues within 4Å:- Chain A: F.176, R.184, R.188
- Ligands: EDO.16
Ligand excluded by PLIPEDO.16: 5 residues within 4Å:- Chain A: L.168, D.174, R.184, R.188
- Ligands: EDO.15
Ligand excluded by PLIPEDO.17: 5 residues within 4Å:- Chain A: N.27, E.55, R.56, H.100, S.104
Ligand excluded by PLIPEDO.18: 7 residues within 4Å:- Chain A: S.135, F.267, S.282, P.283, M.284, C.285
- Ligands: EDO.12
Ligand excluded by PLIPEDO.19: 8 residues within 4Å:- Chain A: L.103, L.108, D.109, A.110, V.111, F.112, I.117
- Ligands: EDO.8
Ligand excluded by PLIPEDO.20: 6 residues within 4Å:- Chain A: R.56, D.57, L.58, T.61, D.114, I.117
Ligand excluded by PLIPEDO.21: 5 residues within 4Å:- Chain A: T.61, F.62, D.114, Q.183
- Ligands: EDO.4
Ligand excluded by PLIPEDO.22: 5 residues within 4Å:- Chain A: E.153, S.154, D.199, K.202
- Ligands: EDO.6
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gewald, R. et al., Discovery of triazines as potent, selective and orally active PDE4 inhibitors. Bioorg.Med.Chem.Lett. (2013)
- Release Date
- 2013-07-10
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4B: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.50 Å
- Oligo State
- monomer
- Ligands
- 1 x 1S1: 2-ethyl-2-{[4-(methylamino)-6-(1H-1,2,4-triazol-1-yl)-1,3,5-triazin-2-yl]amino}butanenitrile(Non-covalent)
- 1 x MG: MAGNESIUM ION(Non-covalent)
- 1 x ZN: ZINC ION(Non-covalent)
- 19 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gewald, R. et al., Discovery of triazines as potent, selective and orally active PDE4 inhibitors. Bioorg.Med.Chem.Lett. (2013)
- Release Date
- 2013-07-10
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4B: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A